The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants who discontinue the study intervention and the reason for discontinuation
Timeframe: Throughout the study period (from rollover visit at Day 1 until the end of study/withdrawal visit)
Number of participants with serious adverse events (SAE)
Timeframe: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)
Number of participants with adverse events of special interest (AESI)
Timeframe: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)